Q3 2017 EPS Estimates for Bristol-Myers Squibb Company (BMY) Reduced by SunTrust Banks

Bristol-Myers Squibb Company (NYSE:BMY) – Equities research analysts at SunTrust Banks dropped their Q3 2017 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a research note issued on Sunday. SunTrust Banks analyst J. Boris now expects that the biopharmaceutical company will post earnings of $0.68 per share for the quarter, down from their prior estimate of $0.70. SunTrust Banks also issued estimates for Bristol-Myers Squibb’s FY2018 earnings at $3.16 EPS.

BMY has been the topic of a number of other reports. BidaskClub upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. William Blair restated an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Monday, June 26th. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.33 target price on the stock in a research report on Wednesday, July 26th. BMO Capital Markets downgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 target price on the stock. in a research report on Wednesday, May 3rd. Finally, Cowen and Company set a $65.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, July 10th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $63.32.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/08/12/q3-2017-eps-estimates-for-bristol-myers-squibb-company-bmy-reduced-by-suntrust-banks-updated.html.

Bristol-Myers Squibb (NYSE BMY) opened at 56.11 on Tuesday. The firm’s 50-day moving average is $55.55 and its 200 day moving average is $54.50. The firm has a market cap of $92.02 billion, a PE ratio of 20.49 and a beta of 1.16. Bristol-Myers Squibb has a 1-year low of $46.01 and a 1-year high of $75.62.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. Bristol-Myers Squibb’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the company earned $0.69 EPS.

A number of hedge funds have recently bought and sold shares of the company. Tradewinds Capital Management LLC boosted its stake in Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 500 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in Bristol-Myers Squibb by 28.4% in the second quarter. Canada Pension Plan Investment Board now owns 4,318,809 shares of the biopharmaceutical company’s stock worth $240,644,000 after buying an additional 956,200 shares during the last quarter. Pointe Capital Management LLC acquired a new stake in Bristol-Myers Squibb during the second quarter worth about $684,000. Trexquant Investment LP acquired a new stake in Bristol-Myers Squibb during the second quarter worth about $223,000. Finally, Mengis Capital Management Inc. boosted its stake in Bristol-Myers Squibb by 2.0% in the second quarter. Mengis Capital Management Inc. now owns 50,836 shares of the biopharmaceutical company’s stock worth $2,832,000 after buying an additional 1,002 shares during the last quarter. 69.56% of the stock is owned by institutional investors and hedge funds.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Investors of record on Friday, July 7th were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Wednesday, July 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.78%. Bristol-Myers Squibb’s payout ratio is 56.73%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

What are top analysts saying about Bristol-Myers Squibb Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit